Table 2 Use of ICIs
From: Ocular adverse events associated with immune checkpoint inhibitors, a scoping review
|  | Total = single use + combination therapy N (%) | Single use N (%) |
|---|---|---|
Anti-PD-1 | Â | 148 (51.0%) |
Pembrolizumab | 93 (32.1%) | 81 |
Nivolumab | 123 (42.5%) | 65 |
Cemiplimab | 1 (0.3%) | 1 |
Sintilimab | 1 (0.3%) | 1 |
Anti-PD-L1 | Â | 22 (7.6%) |
Atezolizumab | 10 (3.4%) | 10 |
Avelumab | 4 (1.4%) | 4 |
Durvalumab | 8 (%) | 6 |
Anti-CTLA-4 | Â | 52 (17.9%) |
Ipilimumab | 116 (40.0%) | 50 |
Tremelimumab | 3 (1.0%) | 1 |